O	0	1	A
O	2	8	cancer
O	9	17	research
O	18	19	(
O	19	21	UK
O	21	22	)
O	23	33	randomized
O	34	39	phase
O	40	42	II
O	43	48	study
O	49	51	of
B-intervention	52	61	idoxifene
O	62	64	in
O	65	73	patients
O	74	78	with
O	79	86	locally
O	87	95	advanced
O	95	96	/
O	96	106	metastatic
O	107	113	breast
O	114	120	cancer
O	121	130	resistant
O	131	133	to
O	134	143	tamoxifen
O	143	144	.

O	145	154	Idoxifene
O	155	157	is
O	158	159	a
O	160	165	novel
O	166	175	selective
O	176	185	oestrogen
O	186	194	receptor
O	195	204	modulator
O	205	206	(
O	206	210	SERM
O	210	211	)
O	212	217	which
O	218	221	had
O	222	229	greater
O	230	237	binding
O	238	246	affinity
O	247	250	for
O	251	254	the
O	255	264	oestrogen
O	265	273	receptor
O	274	275	(
O	275	277	ER
O	277	278	)
O	279	282	and
O	283	290	reduced
O	291	298	agonist
O	299	307	activity
O	308	316	compared
O	317	321	with
O	322	331	tamoxifen
O	332	334	in
O	335	346	preclinical
O	347	354	studies
O	354	355	.

O	356	358	In
O	359	360	a
O	361	371	randomized
O	372	377	phase
O	378	380	II
O	381	386	trial
O	387	389	in
B-total-participants	390	392	56
B-eligibility	393	407	postmenopausal
I-eligibility	408	416	patients
I-eligibility	417	421	with
I-eligibility	422	433	progressive
I-eligibility	434	441	locally
I-eligibility	442	450	advanced
I-eligibility	450	451	/
I-eligibility	451	461	metastatic
I-eligibility	462	468	breast
I-eligibility	469	475	cancer
O	476	478	we
O	479	487	assessed
O	488	495	whether
O	496	505	idoxifene
O	506	512	showed
O	513	521	evidence
O	522	524	of
O	525	533	activity
O	534	542	compared
O	543	547	with
O	548	550	an
O	551	560	increased
O	561	563	40
O	564	566	mg
O	566	567	/
O	567	570	day
O	571	575	dose
O	576	578	of
B-control	579	588	tamoxifen
O	589	591	in
O	592	600	patients
O	601	604	who
O	605	608	had
O	609	619	previously
O	620	632	demonstrated
O	633	643	resistance
O	644	646	to
O	647	650	the
O	651	659	standard
O	660	662	20
O	663	665	mg
O	665	666	/
O	666	669	day
O	670	674	dose
O	675	677	of
O	678	687	tamoxifen
O	687	688	.

O	689	691	Of
B-total-participants	692	694	47
O	695	703	patients
O	704	712	eligible
O	713	716	for
O	717	725	response
O	726	727	(
B-intervention-participants	727	729	25
O	730	739	idoxifene
O	739	740	,
B-control-participants	741	743	22
O	744	753	tamoxifen
O	753	754	)
O	754	755	,
B-iv-bin-abs	756	759	two
B-outcome	760	767	partial
I-outcome	768	777	responses
O	778	781	and
B-iv-bin-abs	782	785	two
B-outcome	786	793	disease
I-outcome	794	808	stabilizations
I-outcome	809	810	(
I-outcome	810	812	SD
I-outcome	812	813	)
O	814	817	for
O	818	819	>
O	819	820	6
O	821	827	months
O	828	832	were
O	833	837	seen
O	838	842	with
O	843	852	idoxifene
O	853	854	(
B-outcome	854	861	overall
I-outcome	862	870	clinical
I-outcome	871	878	benefit
I-outcome	879	883	rate
B-iv-bin-percent	884	886	16
I-iv-bin-percent	886	887	%
O	887	888	,
O	889	891	95
O	891	892	%
O	893	895	CI
O	896	897	4
O	897	898	.
O	898	899	5
O	899	900	-
O	900	902	36
O	902	903	.
O	903	904	1
O	904	905	%
O	905	906	)
O	906	907	.

O	908	911	The
B-outcome	912	918	median
I-outcome	919	927	duration
I-outcome	928	930	of
I-outcome	931	939	clinical
I-outcome	940	947	benefit
O	948	951	was
B-iv-cont-median	952	953	9
I-iv-cont-median	953	954	.
I-iv-cont-median	954	955	8
I-iv-cont-median	956	962	months
O	962	963	.

O	964	966	In
O	967	975	contrast
O	975	976	,
B-cv-bin-abs	977	979	no
B-outcome	980	989	objective
I-outcome	990	999	responses
O	1000	1004	were
O	1005	1009	seen
O	1010	1014	with
O	1015	1018	the
O	1019	1028	increased
O	1029	1031	40
O	1032	1034	mg
O	1034	1035	/
O	1035	1038	day
O	1039	1043	dose
O	1044	1046	of
O	1047	1056	tamoxifen
O	1056	1057	,
O	1058	1066	although
B-cv-bin-abs	1067	1070	two
O	1071	1079	patients
O	1080	1083	had
B-outcome	1084	1086	SD
O	1087	1090	for
O	1091	1092	7
O	1093	1096	and
O	1097	1099	14
O	1100	1106	months
O	1107	1108	(
B-outcome	1108	1116	clinical
I-outcome	1117	1124	benefit
I-outcome	1125	1129	rate
B-cv-bin-percent	1130	1131	9
I-cv-bin-percent	1131	1132	%
O	1132	1133	,
O	1134	1136	95
O	1136	1137	%
O	1138	1140	CI
O	1141	1142	1
O	1142	1143	.
O	1143	1144	1
O	1144	1145	-
O	1145	1147	29
O	1147	1148	.
O	1148	1149	2
O	1149	1150	%
O	1150	1151	)
O	1151	1152	.

O	1153	1162	Idoxifene
O	1163	1166	was
O	1167	1171	well
O	1172	1181	tolerated
O	1182	1185	and
O	1186	1189	the
O	1190	1198	reported
O	1199	1207	possible
B-outcome	1208	1212	drug
I-outcome	1212	1213	-
I-outcome	1213	1220	related
I-outcome	1221	1231	toxicities
O	1232	1236	were
O	1237	1244	similar
O	1245	1247	in
O	1248	1257	frequency
O	1258	1260	to
O	1261	1266	those
O	1267	1271	with
O	1272	1281	tamoxifen
O	1282	1283	(
B-outcome	1283	1286	hot
I-outcome	1287	1294	flushes
B-iv-bin-percent	1295	1297	13
I-iv-bin-percent	1297	1298	%
O	1299	1301	vs
B-cv-bin-percent	1302	1304	15
I-cv-bin-percent	1304	1305	%
O	1305	1306	,
B-outcome	1307	1311	mild
I-outcome	1312	1318	nausea
B-iv-bin-percent	1319	1321	20
I-iv-bin-percent	1321	1322	%
O	1323	1325	vs
B-cv-bin-percent	1326	1328	15
I-cv-bin-percent	1328	1329	%
O	1329	1330	)
O	1330	1331	.

O	1332	1341	Endocrine
O	1342	1345	and
O	1346	1351	lipid
O	1352	1360	analysis
O	1361	1363	in
O	1364	1368	both
O	1369	1375	groups
O	1376	1382	showed
O	1383	1384	a
O	1385	1392	similar
O	1393	1404	significant
O	1405	1409	fall
O	1410	1412	in
B-outcome	1413	1418	serum
I-outcome	1419	1427	follicle
I-outcome	1427	1428	-
I-outcome	1428	1439	stimulating
I-outcome	1440	1447	hormone
I-outcome	1448	1451	and
I-outcome	1452	1463	luteinizing
I-outcome	1464	1471	hormone
O	1472	1477	after
O	1478	1479	4
O	1480	1485	weeks
O	1485	1486	,
O	1487	1495	together
O	1496	1500	with
O	1501	1502	a
O	1503	1514	significant
O	1515	1519	rise
O	1520	1522	in
O	1523	1526	sex
O	1527	1534	hormone
O	1535	1542	binding
O	1543	1551	globulin
O	1552	1558	levels
O	1559	1562	and
O	1563	1565	11
O	1565	1566	%
O	1567	1576	reduction
O	1577	1579	in
B-outcome	1580	1585	serum
I-outcome	1586	1597	cholesterol
I-outcome	1598	1604	levels
O	1604	1605	.

O	1606	1608	In
O	1609	1619	conclusion
O	1619	1620	,
O	1621	1626	while
O	1627	1636	idoxifene
O	1637	1640	was
O	1641	1651	associated
O	1652	1656	with
O	1657	1661	only
O	1662	1668	modest
O	1669	1677	evidence
O	1678	1680	of
O	1681	1689	clinical
O	1690	1698	activity
O	1699	1701	in
O	1702	1710	patients
O	1711	1715	with
O	1716	1725	tamoxifen
O	1725	1726	-
O	1726	1735	resistant
O	1736	1742	breast
O	1743	1749	cancer
O	1749	1750	,
O	1751	1754	its
O	1755	1763	toxicity
O	1764	1771	profile
O	1772	1775	and
O	1776	1783	effects
O	1784	1786	on
O	1787	1796	endocrine
O	1796	1797	/
O	1797	1802	lipid
O	1803	1813	parameters
O	1814	1818	were
O	1819	1826	similar
O	1827	1829	to
O	1830	1835	those
O	1836	1838	of
O	1839	1848	tamoxifen
O	1848	1849	.
